Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 7.88 SEK -1.99%
Market Cap: 881.7m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Investor Relations

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Jorgen Drejer Ph.D.
Founder, Chairman & Deputy CEO
No Bio Available
Mr. Thomas Feldthus M.Sc., MBA
Co-Founder & CEO
No Bio Available
Ms. Anita Milland B.Com.
Chief Financial Officer
No Bio Available
Mr. Karin Sandager Nielsen Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Palle Christophersen M.S., Ph.D.
Executive Vice President of Research
No Bio Available
Mr. Janus Schreiber Larsen
Chief Development Officer
No Bio Available

Contacts

Address
Glostrup
Smedeland 26B
Contacts
+4570705225.0
saniona.com